Core Viewpoint - The article emphasizes the importance of conducting thorough research and independent verification before making investment decisions, highlighting the inherent risks and volatility associated with stock investments [2][3]. Group 1 - The article provides informational content but does not serve as an exhaustive analysis of any featured company [2]. - It clarifies that the predictions and opinions presented are based on a probabilistic approach rather than absolute certainty [2]. - The author has no stock or derivative positions in any of the companies mentioned and does not plan to initiate any such positions in the near future [1]. Group 2 - The article stresses that past performance is not indicative of future results, and no specific investment recommendations are provided [3]. - It notes that the views expressed may not reflect those of the platform as a whole, indicating a diversity of opinions among analysts [3]. - The article highlights that analysts may not be licensed or certified by any regulatory body, which could affect the reliability of the information presented [3].

Core Insights - The Mairs & Power Small Cap Fund reported a return of 2.06% in the first nine months of 2025, underperforming the benchmark Russell 2000 Total Returns Index, which increased by 10.39% [1] - The market remains concentrated in 2025, with a few dominant mega-cap stocks related to artificial intelligence driving most favorable outcomes [1] Company Overview: Knife River Corporation (NYSE:KNF) - Knife River Corporation is a US-based provider of aggregates and construction materials, with a market capitalization of $4.311 billion as of December 10, 2025 [2] - The stock experienced a one-month return of 7.14% but has lost 27.65% of its value over the past 52 weeks [2] Performance Analysis - Knife River Corporation was noted as a significant detractor from the fund's relative performance, facing challenges due to federally funded construction program concerns, weather-related slowdowns, and environmental delays [3] - The number of hedge funds holding Knife River Corporation decreased from 24 in the previous quarter to 18 by the end of the third quarter [4] Investment Perspective - While Knife River Corporation is recognized for its potential, the company is considered less favorable compared to certain AI stocks that are believed to offer greater upside potential and lower downside risk [4]

Core Viewpoint - Nyxoah's Genio system has received a significant reimbursement boost from Medicare, enhancing its commercial viability in the U.S. market, particularly in outpatient settings where Medicare is prevalent [2][4]. Product and Technology Mechanism - Genio utilizes hypoglossal nerve stimulation (HNS) to treat obstructive sleep apnea (OSA) by stimulating the hypoglossal nerve to maintain airway patency, serving as a key alternative to CPAP [6]. - The system features a single incision implantation, reducing surgical trauma and time, with reimbursement rates for outpatient hospitals (HOPD) increased to $45,000 (up approximately 48% from 2025) and for ambulatory surgical centers (ASC) to $42,373 (up approximately 58%) [6][12][17]. - Genio's wireless and external energy supply design avoids complications associated with wires, lowering long-term maintenance costs and repair risks [9][12]. - The selective stimulation design allows for precise control over the movement of the tongue, enhancing the effectiveness of the treatment [13]. CMS Reimbursement Changes - The reclassification of CPT 64568 into the new technology payment category APC 1580 significantly improves reimbursement levels, lowering economic barriers for healthcare providers to adopt Genio [14]. - The increased reimbursement aligns with the trend towards outpatient procedures, making Genio suitable for ASC environments, which are becoming more prevalent [15]. - The patient demographic for OSA overlaps significantly with Medicare beneficiaries, making robust Medicare reimbursement critical for HNS adoption [19]. Competitive Landscape - Nyxoah's primary competitor is Inspire Medical, which has established a dominant market position. However, Genio's unique technology and surgical process differentiate it from Inspire [20]. - Genio's single incision and wireless design make it more suitable for ASC settings, contrasting with Inspire's reliance on hospital resources due to its more complex implantation process [21][22]. - The external energy supply of Genio allows for future innovations and personalized treatments, creating a distinct market position compared to Inspire's implanted power source [23]. Industry Insights - The reimbursement increase reflects a broader trend in the HNS market, indicating a shift from CPAP reliance to more advanced surgical techniques for OSA treatment [24].

Core Viewpoint - The company that manufactures an implant for treating sleep apnea has received an upgrade from Hold to Buy by Stifel [1] Company Summary - The implant is specifically designed for the treatment of sleep apnea, indicating a focus on addressing a significant health issue [1] Industry Summary - The upgrade reflects a positive outlook on the company's potential within the sleep apnea treatment market, suggesting increased investor confidence [1]